Dosiomic predictors of biochemical failure in patients with localized prostate cancer treated with Iodine-125 low-dose-rate brachytherapy

被引:0
|
作者
Masahiro Nakano [1 ]
Shizuo Kaji [2 ]
Shogo Kawakami [1 ]
Hideyasu Tsumura [3 ]
Toshikazu Imae [4 ]
Yuichi Tanaka [5 ]
Kyohei Fujii [5 ]
Takuro Kainuma [1 ]
Ryosuke Yamazaki [1 ]
Ayaka Uchida [1 ]
Hijiri Kaneko [1 ]
Mako Fujino [1 ]
Chizu Hata [5 ]
Yu Murakami [6 ]
Masatoshi Hashimoto [7 ]
Hiromichi Ishiyama [1 ]
机构
[1] Department of Radiation Oncology, Kitasato University School of Medicine, 1-15-1, Kitasato, Minami-ku, Kanagawa, Sagamihara-shi
[2] Institute of Mathematics for Industry, Kyushu University, Fukuoka, Fukuoka
[3] Department of Urology, Kitasato University School of Medicine, Kanagawa, Sagamihara
[4] Department of Radiology, The University of Tokyo Hospital, Bunkyo-ku, Tokyo
[5] Department of Radiology, Kitasato University Hospital, Kanagawa, Sagamihara
[6] Department of Physics, Cancer Institute, Japanese Foundation for Cancer Research, Koto-ku, Tokyo
[7] Department of Medical Engineering and Technology, Kitasato University School of Allied Health Sciences, Sagamihara
基金
日本学术振兴会;
关键词
Biochemical failure; Dosiomic features; Low-dose-rate brachytherapy; Prostate cancer;
D O I
10.1186/s13014-025-02619-6
中图分类号
学科分类号
摘要
Background: This study aimed to identify dosiomic features that have a significant impact on biochemical failure (BCF) following low-dose rate (LDR) brachytherapy treatment using Iodine-125 seeds for prostate cancer and to provide insights into LDR brachytherapy treatment efficacy using a dosiomic approach. Methods: Between January 2005 and February 2015, 1,205 patients with localized prostate cancer underwent Iodine-125 seed implantation without combined external irradiation. A total of 96 patients were selected for this study, including 48 with BCF and 48 without BCF. The patients were divided into two cohorts: derivation and validation. Dose distribution images (DDs) were calculated from computed tomography (CT) images taken one month after implantation. A total of 1,130 dosiomic features, including shape-and-size, histogram, and texture features, were extracted from these DDs, their wavelet-transformed images, and Laplacian-of-Gaussian (LoG)-filtered images. The features obtained were categorized into three groups: shape-and-size (S), histogram (H), and texture (T). The Boruta algorithm was used to eliminate less important features. Two analyses were performed: Analysis A performed a multivariate logistic regression analysis using data from the validation cohort to identify significant features. Analysis B generated logistic regression models using derivation cohort data. The accuracy of BCF prediction was assessed using the validation cohort, with performance measured using the area under the receiver operating characteristic curve (AUC). Results: After the feature reduction process, two, two, and four features remained in the S, H, and T feature groups, respectively. In analysis A, the multivariate logistic regression identified four dominant features, two from each of the S and T groups. In analysis B, the AUC of the logistic regression prediction models using S, H, and all four features were 0.81, 0.77, and 0.86, respectively. Conclusions: Four significant dosiomic features were identified. Notably, three features—elongation, Maximum2DDiameterRow, and wavelet-HHL_Skewness—strongly distinguished patients with favorable prognoses from others. These findings suggest that dosiomic features from postimplant CT and dose distribution may serve as effective factors for evaluating LDR brachytherapy outcomes in patients with prostate cancer. © The Author(s) 2025.
引用
收藏
相关论文
共 50 条
  • [1] Placement of SpaceOAR hydrogel spacer for prostate cancer patients treated with iodine-125 low-dose-rate brachytherapy
    Morita, Masashi
    Fukagai, Takashi
    Hirayama, Kidai
    Yamatoya, Jin
    Noguchi, Tetsuo
    Ogawa, Yu
    Igarashi, Atsushi
    Niiya, Akifumi
    Kato, Masako
    Morota, Madoka
    Oshinomi, Kazuhiko
    Ogawa, Yoshio
    Lederer, John L.
    INTERNATIONAL JOURNAL OF UROLOGY, 2020, 27 (01) : 60 - 66
  • [2] Enhanced activated T cell subsets in prostate cancer patients receiving iodine-125 low-dose-rate prostate brachytherapy
    Kubo, Makoto
    Satoh, Takefumi
    Ishiyama, Hiromichi
    Tabata, Ken-Ichi
    Tsumura, Hideyasu
    Komori, Shoko
    Iwamura, Masatsugu
    Baba, Shiro
    Hayakawa, Kazushige
    Kawamura, Toshihiko
    Obata, Fumiya
    ONCOLOGY REPORTS, 2018, 39 (01) : 417 - 424
  • [3] Clinical outcomes of iodine-125 low-dose-rate brachytherapy for localized prostate cancer: a single-institution review in Japan
    Nakiri, Makoto
    Ogasawara, Naoyuki
    Kurose, Hirofumi
    Ueda, Kosuke
    Chikui, Katsuaki
    Nishihara, Kiyoaki
    Ejima, Kazuhisa
    Uemura, Keiichiro
    Murotani, Kenta
    Muraki, Koichiro
    Hattori, Chikayuki
    Ogo, Etsuyo
    Morimatsu, Yoshitaka
    Ishitake, Tatsuya
    Igawa, Tsukasa
    JOURNAL OF CONTEMPORARY BRACHYTHERAPY, 2022, 14 (02) : 157 - 168
  • [4] Iodine-125 low-dose rate prostate brachytherapy
    Minami, Takafumi
    Fujimoto, Saizo
    Fujita, Kazutoshi
    INTERNATIONAL JOURNAL OF UROLOGY, 2025, 32 (02) : 130 - 137
  • [5] Radiation proctitis after iodine-125 low-dose-rate prostate brachytherapy utilizing SpaceOAR hydrogel
    Morita, Masashi
    Hiramatsu, Aya
    Nishimura, Kota
    Yanagida, Wahei
    Nakamura, Saori
    Yamatoya, Jin
    Noguchi, Tetsuo
    Tanabe, Mayo
    Fukagai, Takashi
    Lederer, John L.
    INTERNATIONAL JOURNAL OF UROLOGY, 2024, 31 (09) : 1001 - 1008
  • [6] Effect of Adequate Local Radiation Dose on Oncological Outcomes in Localized Prostate Cancer Patients Treated With Low-dose-rate Brachytherapy
    Enei, Yuki
    Urabe, Fumihiko
    Miki, Kenta
    Suzuki, Hirotaka
    Iwatani, Kosuke
    Tashiro, Kojiro
    Tsuzuki, Shunsuke
    Furuta, Akira
    Sasaki, Takaya
    Sato, Shun
    Takahashi, Hiroyuki
    Aoki, Manabu
    Kimura, Takahiro
    ANTICANCER RESEARCH, 2023, 43 (07) : 3159 - 3166
  • [7] RADIATION DOSE PREDICTS FOR BIOCHEMICAL CONTROL IN INTERMEDIATE-RISK PROSTATE CANCER PATIENTS TREATED WITH LOW-DOSE-RATE BRACHYTHERAPY
    Ho, Alice Y.
    Burri, Ryan J.
    Cesaretti, Jamie A.
    Stone, Nelson N.
    Stock, Richard G.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (01): : 16 - 22
  • [8] Detection of failure patterns using advanced imaging in patients with biochemical recurrence following low-dose-rate brachytherapy for prostate cancer
    Salerno, Kilian E.
    Turkbey, Baris
    Lindenberg, Liza
    Mena, Esther
    Schott, Erica E.
    Brennan, Alexandra K.
    Roy, Soumyajit
    Shankavaram, Uma
    Patel, Krishnan
    Cooley-Zgela, Theresa
    McKinney, Yolanda
    Wood, Bradford J.
    Pinto, Peter A.
    Choyke, Peter
    Citrin, Deborah E.
    BRACHYTHERAPY, 2022, 21 (04) : 442 - 450
  • [9] Gleason 7 prostate cancer treated with low-dose-rate brachytherapy: lack of impact of primary Gleason pattern on biochemical failure
    Stock, Richard G.
    Berkowitz, Joshua
    Blacksburg, Seth R.
    Stone, Nelson N.
    BJU INTERNATIONAL, 2012, 110 (09) : 1257 - 1261
  • [10] Biochemical control of prostate cancer with iodine-125 brachytherapy alone: experience from a single institution
    Larissa Pereira da Ponte Amadei
    João Luis Fernandes Silva
    Samir Abdallah Hanna
    Cecília Maria Kalil Haddad
    Adriano João Nesrallah
    Heloisa Andrade Carvalho
    Clinical and Translational Oncology, 2012, 14 : 369 - 375